The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.
about
Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failureCauses and consequences of coagulation activation in sepsis: an evolutionary medicine perspectiveNew Consensus Definitions for Sepsis and Septic Shock: Implications for Treatment Strategies and Drug Development?Concise Review: Mesenchymal Stromal Cell-Based Approaches for the Treatment of Acute Respiratory Distress and Sepsis Syndromes.A critical assessment of monitoring practices, patient deterioration, and alarm fatigue on inpatient wards: a review.Association of the immature platelet fraction with sepsis diagnosis and severity.The novel immunotherapeutic oligodeoxynucleotide IMT504 protects neutropenic animals from fatal Pseudomonas aeruginosa bacteremia and sepsisGlobal epidemiology of pediatric severe sepsis: the sepsis prevalence, outcomes, and therapies study.Discordant identification of pediatric severe sepsis by research and clinical definitions in the SPROUT international point prevalence study.Milk fat globule epidermal growth factor-factor 8-derived peptide attenuates organ injury and improves survival in sepsisDifferential alterations of tissue T-cell subsets after sepsis.Decreased Tissue COX5B Expression and Mitochondrial Dysfunction during Sepsis-Induced Kidney Injury in Rats.Trials in adult critical care that show increased mortality of the new intervention: Inevitable or preventable mishaps?Snake Venom Disintegrin Inhibits the Activation of Toll-Like Receptors and Alleviates Sepsis through Integrin alphaVbeta3 Blockade.TNF-related apoptosis-inducing ligand deficiency enhances survival in murine colon ascendens stent peritonitis.Mortality Reduction in Septic Shock by Plasma Adsorption (ROMPA): a protocol for a randomised clinical trial.Neutropenic sepsis is associated with distinct clinical and biological characteristics: a cohort study of severe sepsisToward Smarter Lumping and Smarter Splitting: Rethinking Strategies for Sepsis and Acute Respiratory Distress Syndrome Clinical Trial Design.Therapeutic Administration of a Monoclonal Anti-Il-1β Antibody Protects Against Experimental Melioidosis.Carbon Monoxide Improves Efficacy of Mesenchymal Stromal Cells During Sepsis by Production of Specialized Proresolving Lipid Mediators.Shock induced endotheliopathy (SHINE) in acute critical illness - a unifying pathophysiologic mechanism.Pro-Resolving Molecules-New Approaches to Treat Sepsis?A path to precision in the ICU.Endothelial barrier dysfunction in septic shock.Sepsis in the severely immunocompromised patient.Early Diagnosis of Sepsis: Is an Integrated Omics Approach the Way Forward?Cell-Derived Nanoparticles are Endogenous Modulators of Sepsis With Therapeutic Potential.Recent developments in severe sepsis research: from bench to bedside and back.Pharmacogenomics and pharmacogenetics for the intensive care unit: a narrative review.The immune system's role in sepsis progression, resolution, and long-term outcome.Cytokine storm and sepsis disease pathogenesis.Olfactomedin-4 Is a Candidate Marker for a Pathogenic Neutrophil Subset in Septic Shock.Dynamic diagnostic relationism: a new diagnostic paradigm for complex rapidly changing clinical conditions.Generalizable Biomarkers in Critical Care: Toward Precision Medicine.From amino acids polymers, antimicrobial peptides, and histones, to their possible role in the pathogenesis of septic shock: a historical perspective.Acid sphingomyelinase promotes endothelial stress response in systemic inflammation and sepsis.Peritoneal wash contents used to predict mortality in a murine sepsis model.Comparing the prognostic performance of ASSIST to interleukin-6 and procalcitonin in patients with severe sepsis or septic shock.Ten big mistakes in intensive care medicine.MiR-6835 promoted LPS-induced inflammation of HUVECs associated with the interaction between TLR-4 and AdipoR1 in lipid rafts.
P2860
Q26749027-EEFCF7EF-B9C6-4967-9752-31266906BE17Q26995417-F3145C74-E22E-49EC-8267-DE0B44F327D0Q30235974-275812D3-1D8A-4494-9FF3-7957D48BAD9DQ33722631-E46D1646-BB67-408C-9BCC-3D3FEBC28AE0Q33945216-C14903B6-561A-438C-B7A8-BA03A93027E9Q35011939-0CC74981-AA57-44AA-B380-836770843310Q35105870-BAB9265E-9015-4F25-858F-E655FD0DBFDFQ35672605-06D07217-1FB7-4806-A321-078517D88195Q36067275-494860E6-CD93-4808-855E-9DE505E65442Q36220249-D3AADF99-B845-4CD1-B713-EDAD5FF33199Q36259440-27679B37-E2FB-4EE8-9C0C-50935BF92D27Q36293321-3DA04863-CBCA-4EA1-A8BF-F635A7BA506FQ36614885-0D78EA5E-8B36-4181-BE7B-137CB8A41421Q36700074-5270FA43-D1ED-46F4-AAC6-C32A882EE47CQ37021394-E6F065E3-0E05-4072-98A4-9268BE1B865DQ37101085-6CD7FD97-AB0F-4D43-8903-FF97CD597CF8Q37108504-DEE19141-A5B1-4D9E-A878-D37F1B2D26A9Q37213606-FAF8C866-36FE-4F9C-87ED-B7F506CF0D69Q37327336-82AE8E1C-FBB3-4205-89DC-593026DAEB17Q37420143-F76DDADB-72A8-4758-B88E-2B28CF0F0C2FQ37633753-BF7A776B-0CCF-43D7-9D7E-82919E9F26A0Q37728979-A2ACAE7E-DC1B-4DF7-B5A5-FA3EECE74376Q37733894-F96419AF-5787-4AB0-B9FD-6F61D6BFBB1DQ38270705-9CE92918-0480-4E5C-85E0-A1EACF87AC21Q38458270-58A625C9-7321-47D9-A62D-D74935681C14Q38669814-D40C76AF-4FDE-4C84-834C-A8422F0632EBQ38715255-BE354926-146C-40F6-8CC0-76EC66D322E8Q38724278-241FCD5B-F209-4107-8C3B-A0F90F387B99Q38983589-C579E1F7-C17D-44D7-AEA0-B1B58C7FAB9DQ38991057-91E2164E-43D3-4F76-BF5E-3CC7B758C2DCQ39337284-687A5AFD-5430-48F2-A1C0-1F486816AB81Q39382251-73F5E7D5-CA51-480B-B0F3-AB409006E7FCQ39651351-C342BD88-D8A8-491A-96A4-C07F2F9F5A9EQ40210673-AF8A0F87-B974-4AAB-810E-FF376FB3CB9CQ40331159-90E21B77-2356-4159-B24F-939D40432D20Q40637739-9B573907-CEAD-4657-B18B-681D71325DEFQ41180375-9E997AB1-448D-4609-A2D0-B5320B20C119Q41551089-87FCDFF6-1260-406D-A759-C6A9E88D579AQ41696817-5A09743A-2586-4793-88E4-EDFB00A4E283Q47114602-F745683E-C27F-4A1E-9C32-9F03FDC8856A
P2860
The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?*.
description
2014 nî lūn-bûn
@nan
2014 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
The next generation of sepsis ...... t human activated protein C?*.
@ast
The next generation of sepsis ...... t human activated protein C?*.
@en
The next generation of sepsis ...... t human activated protein C?*.
@nl
type
label
The next generation of sepsis ...... t human activated protein C?*.
@ast
The next generation of sepsis ...... t human activated protein C?*.
@en
The next generation of sepsis ...... t human activated protein C?*.
@nl
prefLabel
The next generation of sepsis ...... t human activated protein C?*.
@ast
The next generation of sepsis ...... t human activated protein C?*.
@en
The next generation of sepsis ...... t human activated protein C?*.
@nl
P2093
P2860
P1476
The next generation of sepsis ...... t human activated protein C?*.
@en
P2093
Henry Masur
R Phillip Dellinger
Steven M Opal
P2860
P304
P356
10.1097/CCM.0000000000000325
P407
P577
2014-07-01T00:00:00Z